Igen Biolab Group
  • Home
  • About us
  • Pipeline
  • Tecnology
  • Press
    • News
    • Press Releases
    • Events
    • Publications
  • Contact
  • English
    • Español
Select Page
MD Anderson and Federation Bio announce collaboration to develop novel microbiome treatment for patients with immunotherapy-resistant cancers

MD Anderson and Federation Bio announce collaboration to develop novel microbiome treatment for patients with immunotherapy-resistant cancers

by Igen BioLab Group | Mar 14, 2023 | News, Press releases

The University of Texas MD Anderson Cancer Center and Federation Bio today announced a strategic collaboration to design and manufacture a complex, synthetic microbial consortium with the goal of expanding the number of cancer patients who respond to immunotherapy....
Studies reveal new insights into gut microbiome impact on immunotherapy response in multiple cancers

Studies reveal new insights into gut microbiome impact on immunotherapy response in multiple cancers

by Igen BioLab Group | Aug 30, 2022 | News

Two studies led by The University of Texas MD Anderson Cancer Center that shed new light on the potential of the gut microbiome as a targetable biomarker to improve responses to immunotherapy were presented today at the 2022 American Society for Clinical Oncology...
Evaluation of the Quality of Life of Patients With Metastatic Non-small Cell Lung Cancer With Supplementary Therapy With IGEN-0206

Evaluation of the Quality of Life of Patients With Metastatic Non-small Cell Lung Cancer With Supplementary Therapy With IGEN-0206

by Igen BioLab Group | Dec 14, 2021 | Publications

A national, multicenter, blind, randomized study of three groups, designed to evaluate the impact on the quality of life of IGEN-0206 (IGEN-0206 is a nutritional product, a food) with nutritional support + standard treatment versus nutritional support + standard...
Altering the microbiome for immunotherapy-resistant urological tumors-An intriguing but still early concept

Altering the microbiome for immunotherapy-resistant urological tumors-An intriguing but still early concept

by Igen BioLab Group | Sep 15, 2021 | Publications

The intestinal microbiome may play an important role in immunomodulation and affect treatment responses to immune checkpoint inhibitor therapy in genitourinary malignancies. Characterizing this impact will require consensus and standardization of microbiome sample...
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

by Igen BioLab Group | Nov 19, 2020 | Publications

Several species of intestinal bacteria have been associated with enhanced efficacy of checkpoint blockade immunotherapy, but the underlying mechanisms by which the microbiome enhances antitumor immunity are unclear. bacteria Several species of intestinal bacteria have...

Recent Posts

  • How the gut microbiome can help predict cancer immunotherapies
  • Intratumoral microbiome is driven by metastatic site and associated with immune histopathological parameters: An ancillary study of the SHIVA clinical trial
  • The Human Microbiota and Skin Cancer
  • Dysbiotic microbiome variation in colorectal cancer patients is linked to lifestyles and metabolic diseases
  • NCI-funded project to study role of gut microbiome in prostate cancer
  • LEGAL NOTICE
  • PRIVACY AND DATA PROTECTION
  • Cookie policy
  • Facebook
  • Twitter
  • Instagram
  • RSS
Design by loComunicas

This website uses its own and third-party cookies in order to analyze the traffic generated for statistical purposes.

You can accept all cookies by clicking "Accept", reject all of them by clicking "Deny" or configure them by clicking "Settings".

For more information on how this site uses cookies and related technologies, you can read our Policy on Cookies

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly necessary cookies

Strictly necessary cookies must always be activated so that we can save your cookie settings preferences.

If you deactivate this cookie, we will not be able to save your preferences. This means that every time you visit this website you will have to activate or deactivate cookies again.

Third party cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, or the most popular pages.

Leaving this cookie active allows us to improve our website.

Please activate the strictly necessary cookies first so that we can save your preferences!

Cookies policy

More information about our cookie policy